JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily.

Trial Profile

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2011

At a glance

  • Drugs Aspirin; Aspirin/dipyridamole
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms JASAP
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2009 Actual patient number (1295) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Actual initiation date changed from Jun 2006 to Apr 2006 as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top